Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Arrowhead Pharmaceuticals (ARWR) Leases (2016 - 2025)

Historic Leases for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $43.4 million.

  • Arrowhead Pharmaceuticals' Leases fell 336.09% to $43.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $43.4 million, marking a year-over-year decrease of 336.09%. This contributed to the annual value of $43.9 million for FY2025, which is 301.4% down from last year.
  • According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Leases is $43.4 million, which was down 336.09% from $43.9 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year Leases high stood at $96.3 million for Q2 2023, and its period low was $33.1 million during Q1 2021.
  • In the last 5 years, Arrowhead Pharmaceuticals' Leases had a median value of $44.2 million in 2024 and averaged $47.7 million.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Leases surged by 7253.9% in 2021 and then plummeted by 5397.85% in 2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Leases (Quarter) stood at $42.0 million in 2021, then increased by 0.1% to $42.0 million in 2022, then increased by 6.88% to $44.9 million in 2023, then dropped by 0.08% to $44.9 million in 2024, then fell by 3.36% to $43.4 million in 2025.
  • Its last three reported values are $43.4 million in Q4 2025, $43.9 million for Q3 2025, and $44.0 million during Q2 2025.